By Counterforce Health Team in Aldurazyme (laronidase) —

Getting Aldurazyme (Laronidase) Covered by Humana in Pennsylvania: Complete Prior Authorization Guide

Answer Box: Quick Start Guide

Aldurazyme (laronidase) is covered by Humana Medicare Advantage plans in Pennsylvania as a Part B medical benefit, but requires prior authorization. The fastest path to approval: (1) Ensure your specialist submits PA with genetic/enzymatic MPS I confirmation, (2) Include detailed infusion monitoring plan and safety protocols, (3) If denied, file internal appeal within 65 days, then Pennsylvania's external review within 4 months. Start today by gathering your MPS I diagnostic results and contacting your prescribing specialist to initiate the PA process through Humana's provider portal.

Table of Contents

Coverage Basics

Is Aldurazyme Covered by Humana?

Yes, Aldurazyme (laronidase) is covered under Humana Medicare Advantage plans, but with important distinctions. Since it's administered via weekly IV infusion in clinical settings, it falls under Medicare Part B (medical benefits) rather than Part D (prescription drug coverage). This means formulary tiers and typical prescription copays don't apply.

Which Humana Plans Cover It?

All Humana Medicare Advantage plans in Pennsylvania that include Part B benefits cover Aldurazyme when medically necessary. Coverage requires:

  • Prior authorization approval
  • Administration at certified infusion facilities
  • Prescription from qualified specialists
  • Confirmed MPS I diagnosis

Prior Authorization Process

Step-by-Step: Fastest Path to Approval

  1. Confirm Diagnosis Documentation (Patient/Family)
    • Gather genetic testing results confirming MPS I
    • Collect enzyme assay showing IDUA deficiency
    • Timeline: Can be done immediately
  2. Specialist Consultation (Patient)
    • Schedule with geneticist, metabolic specialist, or experienced pediatrician
    • Obtain baseline assessments (pulmonary function, imaging)
    • Timeline: 2-4 weeks for appointment and testing
  3. Prior Authorization Submission (Physician)
    • Submit through Humana provider portal
    • Include all required documentation (see checklist below)
    • Timeline: Same day submission possible
  4. Humana Review (Humana)
    • Standard review process
    • May request additional information
    • Timeline: Up to 30 days for Part B decisions
  5. Approval and Infusion Setup (Physician/Patient)
    • Coordinate with certified infusion center
    • Schedule first treatment
    • Timeline: 1-2 weeks after approval

Required Documentation Checklist

Medical Necessity Letter must include:

  • Patient identification and MPS I subtype
  • Genetic testing results (ICD-10: E76.01, E76.02, or E76.03)
  • Current symptoms and functional limitations
  • Baseline pulmonary function tests and imaging
  • Detailed infusion monitoring and safety plan
  • Specialist attestation of medical necessity

Supporting Documents:

  • Complete diagnostic workup confirming MPS I
  • Growth charts (pediatric patients)
  • Specialist consultation notes
  • Emergency management protocols for infusion reactions
Clinician Corner: The medical necessity letter is crucial. Include specific details about glycosaminoglycan accumulation, organ involvement, and expected treatment outcomes. Reference FDA labeling and clinical guidelines for MPS I enzyme replacement therapy.

Timing and Urgency

Standard Timeline

  • Prior Authorization Review: Up to 30 days for Part B medical benefits
  • Appeal Process: 65 days to file internal appeal after denial
  • External Review: 4 months to request Pennsylvania independent review

Expedited Process

If waiting poses serious health risks, request expedited review:

  • How to Request: Call Humana at 1-800-451-4651 with physician certification of urgency
  • Timeline: 72 hours for expedited appeals (24 hours for some pharmacy requests)
  • Requirements: Written statement from prescriber explaining medical urgency

Medical Necessity Criteria

Humana typically requires documentation of:

Requirement What It Means Documentation Needed
Confirmed MPS I Diagnosis Genetic or enzymatic proof Lab results showing IDUA deficiency
Specialist Oversight Qualified prescriber Geneticist, metabolic specialist, or experienced pediatrician
Baseline Assessments Disease severity documentation Pulmonary function tests, imaging studies
Safety Monitoring Plan Infusion reaction management Emergency protocols, trained staff, equipment
Treatment Goals Expected outcomes Functional improvement measures

Common denial reasons include:

  • Missing genetic confirmation
  • Insufficient baseline disease assessments
  • Inadequate infusion monitoring protocols
  • Requests outside FDA-approved indications

Cost Considerations

Medicare Part B Coverage Structure

  • Patient Responsibility: Typically 20% coinsurance after Part B deductible
  • Medigap Plans: May cover additional costs
  • Manufacturer Support: Sanofi offers patient assistance programs

Financial Assistance Options

  • Sanofi Patient Assistance: Income-based support available
  • State Programs: Pennsylvania may offer additional resources for rare diseases
  • Nonprofit Grants: Organizations supporting MPS patients
Note: Aldurazyme's wholesale acquisition cost is approximately $1,113.38 per 2.9 mg/5 mL vial as of January 2025, making financial assistance programs particularly valuable.

Denials and Appeals in Pennsylvania

Pennsylvania residents have robust appeal rights, including a new state-supervised external review process launched in 2024.

Internal Appeal Process

  1. File Within 65 Days of denial notice
  2. Submit via:
  3. Include: Updated medical documentation, specialist letters

Pennsylvania External Review

After exhausting Humana's internal appeals, you can request independent external review:

  • Timeline: Must file within 4 months of final denial
  • Success Rate: Approximately 50% of denials overturned in Pennsylvania's program
  • Process: Submit through Pennsylvania Insurance Department
  • Decision: Binding on Humana if approved

Appeal Documentation

  • Final denial letter from Humana
  • Insurance card and member information
  • Additional medical records supporting necessity
  • Physician certification (for expedited review)

Counterforce Health helps patients navigate complex insurance appeals by analyzing denial letters and crafting evidence-backed responses tailored to each plan's specific requirements. Their platform identifies the exact denial basis and creates point-by-point rebuttals using the right medical citations and clinical documentation. Learn more about their appeal assistance services.

Annual Renewals

Aldurazyme authorization typically requires annual renewal with updated documentation:

Renewal Requirements

  • Current specialist assessment
  • Treatment response documentation
  • Continued medical necessity attestation
  • Updated safety monitoring protocols
  • Evidence of clinical benefit (pulmonary function, mobility assessments)

Timing

  • Submit renewal 30-60 days before current authorization expires
  • Use same documentation standards as initial approval
  • Include comparative assessments showing treatment benefit

Specialty Pharmacy Requirements

Infusion Site Requirements

Aldurazyme must be administered at certified facilities with:

  • Emergency resuscitation equipment
  • Trained medical staff
  • Infusion reaction management protocols
  • Proper drug storage and handling capabilities

Distribution Network

  • Specialty pharmacies coordinate drug delivery to infusion centers
  • Patients don't typically receive drug directly
  • Insurance covers both drug cost and infusion administration

Troubleshooting Common Issues

Portal and System Problems

  • Provider Portal Down: Contact Humana provider services directly
  • Missing Forms: Access current forms at provider.humana.com
  • Status Updates: Check authorization status through member portal

Documentation Issues

  • Incomplete Genetic Testing: Ensure both enzymatic and genetic confirmation
  • Missing Specialist Notes: Coordinate with genetics or metabolic specialists
  • Inadequate Safety Plans: Work with infusion centers to develop comprehensive protocols

Communication Breakdowns

  • Between Providers: Establish clear coordination protocols
  • With Insurance: Maintain detailed records of all interactions
  • With Specialty Pharmacy: Confirm delivery schedules and storage requirements

If you encounter persistent issues, Counterforce Health specializes in turning insurance denials into successful appeals by identifying specific policy requirements and crafting targeted responses that address each plan's unique criteria.

Frequently Asked Questions

Q: How long does Humana prior authorization take for Aldurazyme in Pennsylvania? A: Standard Part B medical benefit reviews take up to 30 days. Expedited reviews for urgent cases are decided within 72 hours when physician certifies medical urgency.

Q: What if Aldurazyme is denied for "not medically necessary"? A: Appeal with additional documentation emphasizing MPS I confirmation, disease progression, and treatment guidelines. Pennsylvania's external review program overturns about 50% of denials.

Q: Can I request peer-to-peer review with Humana? A: Yes, physicians can request peer-to-peer discussions during the appeal process. Contact Humana provider services to arrange clinical consultations.

Q: Does step therapy apply to Aldurazyme? A: Generally no, as Aldurazyme is the only FDA-approved enzyme replacement therapy for MPS I. However, Humana may require documentation of why other management approaches aren't appropriate.

Q: What happens if I need Aldurazyme urgently? A: Request expedited prior authorization with physician certification of medical urgency. Humana must respond within 72 hours for expedited requests.

Q: How do I find certified infusion centers in Pennsylvania? A: Contact your specialist or Humana member services for approved facilities in your area. Infusion centers must meet specific safety and staffing requirements.

Q: Can I appeal if my renewal is denied? A: Yes, the same appeal rights apply to renewal denials. Include documentation of treatment response and continued medical necessity.

Q: What if I move within Pennsylvania during treatment? A: Contact Humana to update your information and ensure continued coverage. You may need to establish care with new local specialists and infusion centers.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare providers and insurance plan directly for personalized guidance. Coverage policies and procedures may change; verify current requirements with Humana and Pennsylvania regulatory authorities.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.